153 Results

People

  1. Aghajanian
    Aghajanian
  2. Chi
    Chi
  3. Barakat
    Barakat
  4. Spriggs
    Spriggs
  5. Abu-Rustum
    Abu-Rustum
  6. Seshan
    Seshan
  7. O'Reilly
    O'Reilly
  8. Riely
    Riely
  9. Rosenberg
    Rosenberg
  10. Sabbatini
    Sabbatini

Groups

  1. Department of Medicine (89)
  2. Solid Tumor Oncology Division (83)
  3. Surgery (47)
  4. Gynecology Disease Management Team (30)
  5. Survivorship Research (27)
  6. Epidemiology and Biostatistics (25)
  7. Biostatistics Service (23)
  8. Gynecologic Medicine Service (21)
  9. GDMT, Medicine (20)
  10. Thoracic Oncology (19)
  1. "platinum"
Formats
  1. Journal Article (141)
  2. Review (8)
  3. Conference Paper (1)
  4. Editorial (1)
  5. Guidelines (1)
  6. Meeting Abstract (1)
Groups
  1. Department of Medicine (89)
  2. Solid Tumor Oncology Division (83)
  3. Surgery (47)
  4. Gynecology Disease Management Team (30)
  5. Survivorship Research (27)
  6. Epidemiology and Biostatistics (25)

More Groups

People
  1. Carol Aghajanian (16)
  2. Dennis Chi (13)
  3. David Spriggs (12)
  4. Richard Barakat (12)
  5. Paul Sabbatini (10)
  6. Dean Bajorin (8)

More People

Years
  1. 2025 (6)
  2. 2024 (10)
  3. 2023 (11)
  4. 2022 (2)
  5. 2021 (5)
  6. 2020 (10)

More Years

Publications
  1. Gynecologic Oncology (20)
  2. Journal of Clinical Oncology (16)
  3. Journal of Thoracic Oncology (9)
  4. Cancer (8)
  5. The Oncologist (7)
  6. International Journal of Radiation Oncology, Biology, Physics (5)

More Publications

Publishers
  1. Elsevier Inc. (51)
  2. American Society of Clinical Oncology (17)
  3. Wiley Blackwell (11)
  4. Elsevier Science, Inc. (9)
  5. Oxford University Press (9)
  6. Lippincott Williams & Wilkins (8)

More Publishers

Results (153)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Population pharmacokinetic model of platinum disposition in cancer patients receiving cisplatin and randomized to 5-HT3 antagonist antiemetic drugs
    Journal Article

    Thompson, L. E.; Ghimire, A.; Wen, X.; Kim, C.; Doherty, C. L.; Buckley, B. T.; Bowles, D. W.; O'Bryant, C. L.; Jaimes, E. A.; Aleksunes, L. M.; more...
    Journal of Clinical Pharmacology (2025)

    Fulltext@MSK | Save
  • A study to learn how well enfortumab vedotin (EV) with pembrolizumab works and how safe it is in people with advanced urothelial cancer: A plain language summary of the EV-302/KEYNOTE-A39 study
    Editorial

    Powles, T.; Valderrama, B. P.; Gupta, S.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Iyer, G.; Vulsteke, C.; Park, S. H.; Shin, S. J.; more...
    Future Oncology (2025)

    Fulltext@MSK | Save
  • REZILIENT3: Randomized phase III study of first-line zipalertinib plus chemotherapy in patients with EGFR exon 20 insertion-mutated NSCLC
    Journal Article

    Heymach, J. V.; Yu, H. A.; Besse, B.; Cheng, Y.; Tan, D. S. W.; Wei, L.; Wacheck, V.; Nishio, M.
    Future Oncology (2025)

    Fulltext@MSK | Save
  • Determinants of successful minimally invasive surgery for resectable non–small cell lung cancer after neoadjuvant therapy
    Conference Paper

    Chu, N. Q.; Tan, K. S.; Dycoco, J.; Adusumilli, P. S.; Bains, M. S.; Bott, M. J.; Downey, R. J.; Gray, K. D.; Huang, J.; Isbell, J. M.; more...
    Mosby Elsevier (2025)

    Fulltext@MSK | Save
  • Consolidation ALK tyrosine kinase inhibitors versus durvalumab or observation after chemoradiation in unresectable stage III ALK-positive NSCLC
    Journal Article

    Nassar, A. H.; Jayakrishnan, R.; Feng, J.; Shepherd, F.; Adib, E.; Cheung, J. M.; Lin, J. J.; Liu, Y.; Lin, S. H.; Parikh, K.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis
    Journal Article

    Liu, Y. L.; Mathews, C. A.; Simpkins, F.; Cadoo, K. A.; Provencher, D.; McCormick, C. C.; ElNaggar, A. C.; Altman, A. D.; Gilbert, L.; Black, D.; more...
    Cancer (2025)

    Fulltext@MSK | Save
  • Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor-resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer
    Journal Article

    Yang, J. C. H.; Lee, D. H.; Lee, J. S.; Fan, Y.; de Marinis, F.; Iwama, E.; Inoue, T.; Rodríguez-Cid, J.; Zhang, L.; Yang, C. T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
    Journal Article

    Skoulidis, F.; Araujo, H. A.; Do, M. T.; Qian, Y.; Sun, X.; Cobo, A. G.; Le, J. T.; Montesion, M.; Palmer, R.; Jahchan, N.; more...
    Nature (2024)

    Fulltext@MSK | Save
  • Neoadjuvant and adjuvant treatments for early stage resectable NSCLC: Consensus recommendations from the international association for the study of lung cancer
    Review

    Spicer, J. D.; Cascone, T.; Wynes, M. W.; Ahn, M. J.; Dacic, S.; Felip, E.; Forde, P. M.; Higgins, K. A.; Kris, M. G.; Mitsudomi, T.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers
    Journal Article

    Belli, C.; Boscolo Bielo, L.; Repetto, M.; Crimini, E.; Scalia, R.; Diana, A.; Orefice, J.; Ascione, L.; Pellizzari, G.; Fusco, N.; more...
    The Oncologist (2024)

    Fulltext@MSK | Save